From ESC 2024 - EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population
An analysis of the EMPACT-MI study presented at the European Society of Cardiology (ESC) Congress 2024 underlines the safety of initiating SGLT2 inhibitor therapy in patients with a history of acute myocardial infarction.
The analysis demonstrates use of the SGLT2 inhibitor empagliflozin (Jardiance) provided meaningful reductions in heart failure events among patients in the trial, regardless of baseline kidney function.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
